Twist and Cancer Research Horizons sign antibody library platform deal
19 Jul 2023
License out/inADC
Preview
Source: Pharmaceutical Technology
The library of libraries is a collection of synthesised antibody libraries. Credit: angellodeco / Shutterstock.com.
Twist Bioscience and Cancer ResearchCancer Research UK’s innovation arm Cancer Research HorizonsCancer Research Horizons have signed an agreement to license a “library of libraries”.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsBromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) Drugs... GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Vilamakitug in Pancreatic Cancer GlobalData
View allCompanies IntelligenceTwist Bioscience CorpCancer Research HorizonsView all
Twist will obtain a library access fee and will be eligible for annual maintenance fees. It will also receive a portion of the revenue generated from any assets sold or transferred.
Cancer Research Horizons Therapeutic Innovation CEO Hamish Ryder stated: “We’re delighted to partner with Twist Bioscience, an exciting technology platform company that will enhance our antibody discovery capabilities with their highly diverse phage display libraries.
“We look forward to using this technology to accelerate the delivery of high-quality therapeutics and diagnostics to cancer patients, in collaboration with our academic and industrial partners.”
The library of libraries is a collection of synthesised antibody libraries, designed using naturally occurring sequences and incorporating innovative structural and developability features to encompass a range of antibody drug targets.
Twist Bioscience CEO and co-founder Emily Leproust stated: “Cancer Research Horizons acts as a conduit between academia and industry, with our collaboration enabling early-stage antibody identification through access to our “library of libraries.”
“With two mission-driven organisations aligning behind innovative technology solutions to improve health to make the world a better place, the opportunity to identify new biotherapeutics offers tremendous hope to those who need it most.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.